Anti-CD68 antibody [EPR23917-164] (Ab283654)

特异性

Mouse unsuitable for IHC-Fr application

Anti-CD68 antibody [EPR23917-164] (ab283654) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt (Intra), ICC/IF, IHC-Fr, IHC-P, mIHC, and WB. Abcam's high quality manufacturing and validation processes ensure Anti-CD68 antibody [EPR23917-164] (ab283654) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-CD68 antibody [EPR23917-164] (ab283654) has been confirmed by Western Blot testing in CD68 knockout RAW 264.7 cells (cell lysate ab280106 ). Anti-CD68 antibody [EPR23917-164] (ab283654) specifically detects CD68 (UniProt ID: P31996; Molecular weight: 33kDa) and is sold in a convenient trial size to enable initial testing (20 µL) and larger sizes for subsequent scaling up experiments (100 µL and 1 mL). Conjugation-ready, carrier free format available for antibody clone EPR23917-164 - ab283667. Antibody clone EPR23917-164 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 647, Alexa Fluor ® 594, APC, Alexa Fluor ® 488 ( ab305214, ab312903, ab317758, ab319086 ). CD68 levels is implicated in autoimmune conditions like rheumatoid arthritis, where macrophages contribute to joint inflammation and damage. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies.